Liver CirculationNCT07337291
Double Stent for Biliary Stones in Cirrhotic Patients
A study testing Single 10 Fr Plastic Biliary Stent, Two 10 Fr Plastic Biliary Stent and Single 11.5 Fr Plastic Biliary Stent in people with Liver Circulation and Choledocholithiasis, run by National Liver Institute, Egypt at 1 site in Egypt.
Trial summary
This prospective, single-center, interventional study enrolled 400 cirrhotic patients with large or complex common bile duct (CBD) stones that could not be removed during an initial Endoscopic Retrograde Cholangiopancreatography (ERCP). Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Liver Circulation, Choledocholithiasis, Stent
- What is being tested?
- Single 10 Fr Plastic Biliary Stent, Two 10 Fr Plastic Biliary Stent and Single 11.5 Fr Plastic Biliary Stent
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2022to 1 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults with established liver cirrhosis.
- Presence of large or complex common bile duct (CBD) stones that were non-retrievable during the initial ERCP.
- Classified as high-risk due to moderate to severe liver disease and/or substantial comorbidities, making them unable to safely tolerate extended endoscopic procedures or surgical intervention.
- Clinically stable and capable of undergoing the scheduled diagnostic and therapeutic procedures.
- Provided signed informed consent before enrollment.
Who cannot join
- Non-cirrhotic patients.
- Patients with non-calculous causes of biliary obstruction (e.g., portal biliopathy, benign biliary strictures, or malignant biliary obstruction).
- Acute suppurative cholangitis.
- Contraindications to ERCP.
- Inability to complete the scheduled 12-month follow-up time.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
National Liver Institute, Menoufia University, Egypt.
Shibīn al Kawm, Menoufia, 32511
About this study
Official title: Double Versus Single Plastic Stents for Non-Retrievable Biliary Stones in Cirrhotic Patients
This prospective, single-center, interventional study enrolled 400 cirrhotic patients with large or complex common bile duct (CBD) stones that could not be removed during an initial Endoscopic Retrograde Cholangiopancreatography (ERCP). The study compared four different plastic biliary stenting strategies (single 10 Fr, double 10 Fr, single 11.5 Fr, and single 10 Fr pigtail stents) to determine the optimal approach for facilitating successful stone clearance in a subsequent ERCP and minimizing complications in this high-risk patient population.
Read the detailed description
Background and Rationale: The primary treatment for choledocholithiasis is Endoscopic Retrograde Cholangiopancreatography (ERCP) with sphincterotomy. However, complete stone clearance fails in 10-15% of cases involving complex choledochal stones (e.g., larger than 15 mm and/or more than 3 stones), often necessitating recurrent ERCP procedures. This challenge is compounded in high-risk patients, such as the elderly or those with substantial comorbidities, who cannot tolerate prolonged procedures. Failure to extract stones can also be attributed to anatomical factors like complex stones, periampullary diverticula, or ductal anomalies. While alternative methods like ESWL or lithotripsy exist, they are not universally available. Temporary plastic biliary stent placement is a safe and effective alternative, providing biliary drainage and acting as a bridge to subsequent stone removal. Short-term stenting can reduce stone size and improve the success rate of later extraction.
The aim of this work is to evaluate the role and efficiency of different types or different numbers of plastic stent application in the treatment of non-retrievable large biliary stones in liver cirrhosis.
Study Design and Setting: This is a prospective, single-center, interventional study conducted at the National Liver Institute, Menoufia University, Egypt, between January 2022 and January 2025. The study was authorized by the Institutional Ethics Committee (Approval No.: 00787/2025). A total of 400 cirrhotic patients with calculous biliary obstruction were included. Study Population and Eligibility: Participants were adults with established liver cirrhosis classified as high-risk due to moderate to severe liver disease and/or substantial comorbidities, who could not safely tolerate extended endoscopic or surgical intervention. They all presented with large or complex Common Bile Duct (CBD) stones that could not be removed during the initial ERCP. All enrolled subjects were clinically stable and provided signed informed consent. Exclusion criteria included non-cirrhotic patients, non-calculous causes of biliary obstruction (e.g., portal biliopathy, malignant obstruction), acute suppurative cholangitis, ERCP contraindications, or inability to complete the scheduled 12-month follow-up.
Interventions and Study Groups: Enrolled individuals were allocated into four parallel groups based on the type and size of the plastic biliary stent used during ERCP: Group 1 (Single plastic stent, 10 cm × 10 Fr), Group 2 (Double plastic stents, each 10 cm × 10 Fr), Group 3 (Single plastic stent, 10 cm × 11.5 Fr), and Group 4 (Single pigtail stent, 10 cm × 10 Fr). ERCP Procedure: All ERCPs were performed by expert hepatobiliary endoscopists under general anesthesia using a standard side-viewing duodenoscope. Following selective CBD cannulation, stone extraction was attempted. When complete clearance was not achievable, the appropriate plastic stent(s) were placed over a guidewire, with or without a previous sphincterotomy. Prolonged procedures, advanced lithotripsy techniques, and chemical stone dissolution were deliberately avoided due to the high-risk nature of the study population. Data Collection and Follow-up: Thorough clinical and demographic data were systematically documented. Baseline laboratory investigations included renal function tests, CBC, CRP, pancreatic enzymes, and a full liver biochemical profile. Imaging (ultrasonography and MRCP) was used to characterize stone size, number, and biliary anatomy. Patients were observed for a minimum of 24 hours post-procedure. Follow-up assessments were scheduled at 1 month and subsequently at 3-6 month intervals or on demand. The total monitoring period was 12 months, with the final assessment completed by January 2026. Follow-up involved clinical assessment, laboratory tests, and abdominal radiographs to assess biliary drainage and stent patency. Patients with signs of stent malfunction underwent repeat ERCP.
Outcome Measures: The main outcomes were stent patency and successful stone clearance at the second ERCP. Secondary objectives included reduction in stone size, all-cause mortality throughout the follow-up period, and procedure-related complications (stent migration, cholangitis, post-ERCP pancreatitis, and hemorrhage).
Statistical Analysis: Statistical analysis will be performed using IBM SPSS Statistics (version 22). Comparisons among groups will be completed using the chi-square (χ²) test or Monte Carlo correction for categorical variables, one-way ANOVA for normally distributed continuous variables, and the Kruskal-Wallis test for non-normally distributed variables. A p-value ≤ 0.05 is considered statistically significant.
- Conditions
- Liver Circulation, Choledocholithiasis, Stent
- Being tested
- Single 10 Fr Plastic Biliary Stent, Two 10 Fr Plastic Biliary Stent, Single 11.5 Fr Plastic Biliary Stent, Single 10 Fr Pigtail Stent
- Keywords
- ERCP, Biliary Stent, Double Stent, Liver Cirrhosis, Non-Retrievable Stones, High-Risk Patients
- Medical subject headings
- Choledocholithiasis, Liver Cirrhosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Single 10 Fr Plastic Biliary StentDevice
Single 10 Fr, 10 cm plastic stent placed endoscopically.
Two 10 Fr Plastic Biliary StentDevice
Two 10 Fr, 10 cm plastic stents placed endoscopically.
Single 11.5 Fr Plastic Biliary StentDevice
Single 11.5 Fr, 10 cm plastic stent placed endoscopically.
Single 10 Fr Pigtail StentDevice
Single 10 Fr, 10 cm pigtail plastic stent placed endoscopically.
| Study group | Role | What they receive |
|---|---|---|
| Single 10 Fr Plastic Stent | Experimental | Placement of a single 10 French (Fr), 10 cm plastic biliary stent. Receives: Device: Single 10 Fr Plastic Biliary Stent |
| Double 10 Fr Plastic Stents | Experimental | Placement of two 10 French (Fr), 10 cm plastic biliary stents side-by-side. Receives: Device: Two 10 Fr Plastic Biliary Stent |
| Single 11.5 Fr Plastic Stent | Experimental | Placement of a single 11.5 French (Fr), 10 cm plastic biliary stent. Receives: Device: Single 11.5 Fr Plastic Biliary Stent |
| Single 10 Fr Pigtail Stent | Experimental | Placement of a single 10 French (Fr), 10 cm pigtail plastic biliary stent. Receives: Device: Single 10 Fr Pigtail Stent |
What is being measured
The primary outcome is the main question the study is designed to answer.
Stent Patency
Time from stent placement until clinical or biochemical evidence of stent occlusion (e.g., cholangitis, elevated liver enzymes, or imaging findings).
Measured: 6 months
Successful Stone Clearance in Second ERCP
The proportion of patients in each group achieving complete clearance of common bile duct stones during the second, planned ERCP session.
Measured: 6 months
Secondary outcomes (3)
Incidence of Procedure-Related Complications
Incidence of adverse events, including stent migration, cholangitis, post-ERCP pancreatitis, and hemorrhage.
Measured: From stenting until 30 days after the second ERCP.
Reduction in Stone Size
Mean reduction in the largest stone diameter, measured by cholangiography or MRCP, between initial stenting and the second ERCP.
Measured: 6 months
All-Cause Mortality
The number of deaths from any cause during the study follow-up period
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study start1 Jan 2022
- Primary completion1 Jan 2025
- Study completion1 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Liver CirculationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 400 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Liver Institute, Egypt
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07337291
- Sponsor's protocol ID
- 01282612295
- Other IDs
- 00787
- Status last verified
- Dec 2025
- First submitted
- 1 Jan 2026
- Last updated
- 13 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Lee TH, Han JH, Kim HJ, Park SM, Park SH, Kim SJ. Is the addition of choleretic agents in multiple double-pigtail biliary stents effective for difficult common bile duct stones in elderly patients? A prospective, multicenter study. Gastrointest Endosc. 2011 Jul;74(1):96-102. doi: 10.1016/j.gie.2011.03.005. Epub 2011 Apr 30.
PubMed 21531412Horiuchi A, Nakayama Y, Kajiyama M, Kato N, Kamijima T, Graham DY, Tanaka N. Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc. 2010 Jun;71(7):1200-1203.e2. doi: 10.1016/j.gie.2009.12.055. Epub 2010 Apr 18.
PubMed 20400079Binmoeller KF, Schafer TW. Endoscopic management of bile duct stones. J Clin Gastroenterol. 2001 Feb;32(2):106-18. doi: 10.1097/00004836-200102000-00004.
PubMed 11205644
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Double Versus Single Plastic Stents for Non-Retrievable Biliary Stones in Cirrhotic Patients
- ClinicalTrials.gov ID
- NCT07337291
- Acronym / sponsor ID
- 01282612295
- Conditions
- Liver Circulation, Choledocholithiasis, Stent
- Keywords
- ERCP, Biliary Stent, Double Stent, Liver Cirrhosis, Non-Retrievable Stones, High-Risk Patients
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 400 participants (actual)
- Lead sponsor
- National Liver Institute, EgyptUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 1 Jan 2025 (actual)
- Study completion
- 1 Jan 2026 (actual)
- First posted
- 13 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, single-center, interventional study enrolled 400 cirrhotic patients with large or complex common bile duct (CBD) stones that could not be removed during an initial Endoscopic Retrograde Cholangiopancreatography (ERCP). The study compared four different plastic biliary stenting strategies (single 10 Fr, double 10 Fr, single 11.5 Fr, and single 10 Fr pigtail stents) to determine the optimal approach for facilitating successful stone clearance in a subsequent ERCP and minimizing complications in this high-risk patient population.
Detailed description
Background and Rationale: The primary treatment for choledocholithiasis is Endoscopic Retrograde Cholangiopancreatography (ERCP) with sphincterotomy. However, complete stone clearance fails in 10-15% of cases involving complex choledochal stones (e.g., larger than 15 mm and/or more than 3 stones), often necessitating recurrent ERCP procedures. This challenge is compounded in high-risk patients, such as the elderly or those with substantial comorbidities, who cannot tolerate prolonged procedures. Failure to extract stones can also be attributed to anatomical factors like complex stones, periampullary diverticula, or ductal anomalies. While alternative methods like ESWL or lithotripsy exist, they are not universally available. Temporary plastic biliary stent placement is a safe and effective alternative, providing biliary drainage and acting as a bridge to subsequent stone removal. Short-term stenting can reduce stone size and improve the success rate of later extraction.
The aim of this work is to evaluate the role and efficiency of different types or different numbers of plastic stent application in the treatment of non-retrievable large biliary stones in liver cirrhosis.
Study Design and Setting: This is a prospective, single-center, interventional study conducted at the National Liver Institute, Menoufia University, Egypt, between January 2022 and January 2025. The study was authorized by the Institutional Ethics Committee (Approval No.: 00787/2025). A total of 400 cirrhotic patients with calculous biliary obstruction were included. Study Population and Eligibility: Participants were adults with established liver cirrhosis classified as high-risk due to moderate to severe liver disease and/or substantial comorbidities, who could not safely tolerate extended endoscopic or surgical intervention. They all presented with large or complex Common Bile Duct (CBD) stones that could not be removed during the initial ERCP. All enrolled subjects were clinically stable and provided signed informed consent. Exclusion criteria included non-cirrhotic patients, non-calculous causes of biliary obstruction (e.g., portal biliopathy, malignant obstruction), acute suppurative cholangitis, ERCP contraindications, or inability to complete the scheduled 12-month follow-up.
Interventions and Study Groups: Enrolled individuals were allocated into four parallel groups based on the type and size of the plastic biliary stent used during ERCP: Group 1 (Single plastic stent, 10 cm × 10 Fr), Group 2 (Double plastic stents, each 10 cm × 10 Fr), Group 3 (Single plastic stent, 10 cm × 11.5 Fr), and Group 4 (Single pigtail stent, 10 cm × 10 Fr). ERCP Procedure: All ERCPs were performed by expert hepatobiliary endoscopists under general anesthesia using a standard side-viewing duodenoscope. Following selective CBD cannulation, stone extraction was attempted. When complete clearance was not achievable, the appropriate plastic stent(s) were placed over a guidewire, with or without a previous sphincterotomy. Prolonged procedures, advanced lithotripsy techniques, and chemical stone dissolution were deliberately avoided due to the high-risk nature of the study population. Data Collection and Follow-up: Thorough clinical and demographic data were systematically documented. Baseline laboratory investigations included renal function tests, CBC, CRP, pancreatic enzymes, and a full liver biochemical profile. Imaging (ultrasonography and MRCP) was used to characterize stone size, number, and biliary anatomy. Patients were observed for a minimum of 24 hours post-procedure. Follow-up assessments were scheduled at 1 month and subsequently at 3-6 month intervals or on demand. The total monitoring period was 12 months, with the final assessment completed by January 2026. Follow-up involved clinical assessment, laboratory tests, and abdominal radiographs to assess biliary drainage and stent patency. Patients with signs of stent malfunction underwent repeat ERCP.
Outcome Measures: The main outcomes were stent patency and successful stone clearance at the second ERCP. Secondary objectives included reduction in stone size, all-cause mortality throughout the follow-up period, and procedure-related complications (stent migration, cholangitis, post-ERCP pancreatitis, and hemorrhage).
Statistical Analysis: Statistical analysis will be performed using IBM SPSS Statistics (version 22). Comparisons among groups will be completed using the chi-square (χ²) test or Monte Carlo correction for categorical variables, one-way ANOVA for normally distributed continuous variables, and the Kruskal-Wallis test for non-normally distributed variables. A p-value ≤ 0.05 is considered statistically significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Single 10 Fr Plastic Stent | Experimental | Device: Single 10 Fr Plastic Biliary StentPlacement of a single 10 French (Fr), 10 cm plastic biliary stent. |
| Double 10 Fr Plastic Stents | Experimental | Device: Two 10 Fr Plastic Biliary StentPlacement of two 10 French (Fr), 10 cm plastic biliary stents side-by-side. |
| Single 11.5 Fr Plastic Stent | Experimental | Device: Single 11.5 Fr Plastic Biliary StentPlacement of a single 11.5 French (Fr), 10 cm plastic biliary stent. |
| Single 10 Fr Pigtail Stent | Experimental | Device: Single 10 Fr Pigtail StentPlacement of a single 10 French (Fr), 10 cm pigtail plastic biliary stent. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults with established liver cirrhosis.
- Presence of large or complex common bile duct (CBD) stones that were non-retrievable during the initial ERCP.
- Classified as high-risk due to moderate to severe liver disease and/or substantial comorbidities, making them unable to safely tolerate extended endoscopic procedures or surgical intervention.
- Clinically stable and capable of undergoing the scheduled diagnostic and therapeutic procedures.
- Provided signed informed consent before enrollment.
Key exclusion criteria (5 listed)
- Non-cirrhotic patients.
- Patients with non-calculous causes of biliary obstruction (e.g., portal biliopathy, benign biliary strictures, or malignant biliary obstruction).
- Acute suppurative cholangitis.
- Contraindications to ERCP.
- Inability to complete the scheduled 12-month follow-up time.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Single 10 Fr Plastic Biliary StentSingle 10 Fr, 10 cm plastic stent placed endoscopically. | Device | Single 10 Fr Plastic Stent |
| Two 10 Fr Plastic Biliary StentTwo 10 Fr, 10 cm plastic stents placed endoscopically. | Device | Double 10 Fr Plastic Stents |
| Single 11.5 Fr Plastic Biliary StentSingle 11.5 Fr, 10 cm plastic stent placed endoscopically. | Device | Single 11.5 Fr Plastic Stent |
| Single 10 Fr Pigtail StentSingle 10 Fr, 10 cm pigtail plastic stent placed endoscopically. | Device | Single 10 Fr Pigtail Stent |
Primary outcome
Stent Patency
Time frame: 6 months
Time from stent placement until clinical or biochemical evidence of stent occlusion (e.g., cholangitis, elevated liver enzymes, or imaging findings).
Successful Stone Clearance in Second ERCP
Time frame: 6 months
The proportion of patients in each group achieving complete clearance of common bile duct stones during the second, planned ERCP session.
3 secondary outcomes
Incidence of Procedure-Related Complications
Time frame: From stenting until 30 days after the second ERCP.
Reduction in Stone Size
Time frame: 6 months
All-Cause Mortality
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
- Background: PubMed 21531412Lee TH, Han JH, Kim HJ, Park SM, Park SH, Kim SJ. Is the addition of choleretic agents in multiple double-pigtail biliary stents effective for difficult common bile duct stones in elderly patients? A prospective, multicenter study. Gastrointest Endosc. 2011 Jul;74(1):96-102. doi: 10.1016/j.gie.2011.03.005. Epub 2011 Apr 30.
- Background: PubMed 20400079Horiuchi A, Nakayama Y, Kajiyama M, Kato N, Kamijima T, Graham DY, Tanaka N. Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc. 2010 Jun;71(7):1200-1203.e2. doi: 10.1016/j.gie.2009.12.055. Epub 2010 Apr 18.
- Background: PubMed 11205644Binmoeller KF, Schafer TW. Endoscopic management of bile duct stones. J Clin Gastroenterol. 2001 Feb;32(2):106-18. doi: 10.1097/00004836-200102000-00004.
- Individual participant dataSharing planned: Undecided
Related trials for Liver Circulation
RecruitingPhase 1
IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease
Fontan Circulation
Recruiting
ENLIGHT Trial: ESG With Fundal Mucosal Ablation
Obesity, Obesity (Body Mass Index >30 kg/m2)
RecruitingPhase 2
Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation
Liver Transplant
Not yet recruitingPhase 1/2
RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure
Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE)
Recruiting
qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver
Transarterial Embolism, Transarterial Chemoembolization
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Single 10 Fr Plastic Biliary Stent, Two 10 Fr Plastic Biliary Stent and Single 11.5 Fr Plastic Biliary Stent in people with Liver Circulation and Choledocholithiasis, run by National Liver Institute, Egypt at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Stent Patency (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07337291, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.